Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Completed1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

unknown125%
completed125%
terminated125%
not_yet_recruiting125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

NCT04644185
not_yet_recruitingphase_2

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

NCT04709328
completedphase_1

Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

NCT04483375
unknownphase_2

The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

NCT04683328

Clinical Trials (4)

Showing 4 of 4 trials
NCT04644185Phase 2

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Terminated
NCT04709328Phase 2

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

Not Yet Recruiting
NCT04483375Phase 1

Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

Completed
NCT04683328Phase 2

The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4